The Juvenile Diabetes Research Foundation has named Alan J. Lewis, Ph.D., as president and CEO.
InCode BioPharmaceutics has appointed Kevin L. Stark, Ph.D. as president and CEO.
ZymoGenetics CEO Bruce Carter says he will step down from his post in January. He is being replaced by Douglas Williams.
Celsion Corp. named Sean Moran as senior vice president and CFO.
Caroline Loewy, CFO, provided written notice of her resignation from Poniard Pharmaceuticals to pursue another employment opportunity.
BioMarin Pharmaceutical announced that Chief Medical Officer Emil Kakkis will retire from the company on February 27, 2009.
Eurand NV named Ruth Thieroff-Ekerdt, M.D., to the newly created position of chief medical officer of Eurand Pharmaceuticals.
Elan has appointed Mary Stutts as the company's new senior vice president and head of corporate relations.
Cetero Research has promoted Chinna Pamidi, PhD, president of bioanalytical operations; Alan Copa, PharmD, to president of Clinical Operations; and Michael Murren to CFO.
Kevin Smith has joined Arysta LifeScience Corporation as chief operating officer of the company's European business unit.
Cyntellect has named Andre Lubarsky as the company's director of sales - North America.
Bernard Mulder, MD, MBA, has joined Avantium to lead the business development team for its pharmaceutical business.
David R. King has been appointed as Diasome Pharmaceuticals' chairman of the board.
Transdel Pharmaceuticals announced that Lynn Swann has been appointed to the company's board of directors.
Sangamo BioSciences has named Paul B. Cleveland to its board of directors,
Pacific Biosciences named Elaine Mardis to its Scientific Advisory Board.
Agios Pharmaceuticals has named several scientific advisors. They are: Chi Van Dang, M.D., Ph.D., of Johns Hopkins University; Joshua Rabinowitz, M.D., Ph.D., of Princeton University; Clary Clish, Ph.D., of Broad Institute, Massachusetts Institute of Technology and Harvard University; Matthew Vander Heiden, M.D., Ph.D., of Dana Farber Cancer Institute; and James Bradner, M.D., of Dana Farber Cancer Institute.